Navigation Links
Anaphore Appoints Paul A. Grayson President and CEO
Date:6/20/2011

biopharmaceutical company focused on the development of therapies that act through stem cell modulation.  Before this, he was managing director of Sanderling Ventures where he was a founding board member of multiple portfolio companies including: Calcimedica, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), and Naviscan.  Prior to Sanderling, Grayson served as the founding Chairman and CEO of Senomyx Inc. and part of the founding management team of Aurora Biosciences (acquired by Vertex).

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimer therapeutics potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property, including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimer therapeutics against targets in a wide range of therapeutic areas, including rare diseases.

Anaphore recently formed a partnership with Mitsubishi Tanabe Pharma Corporation to discover and develop Atrimer drug candidates for the treatment of autoimmune disorders. Since its founding in 2008, Anaphore has raised $38 million in financing
'/>"/>

SOURCE Anaphore
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
2. ID Analytics Appoints Chief Information Officer
3. ID Analytics Appoints Chief Information Officer
4. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
5. BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer
6. Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative
7. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
8. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. The Science Coalitions 10 questions for the presidential debate
11. Haag honored with Presidential Early Career Scientists Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... most people have intuitive reactions to Web sites, a group ... those emotions and more. Aude Dufresne, a professor ... team of researchers that are designing a new software to ... put, the new software measures everything in Web users from ...
... hour when the reef-building "rice coral" off Oahu will ... coral larvae go. From June 11-16, 2010, the ... Kewalo Marine Laboratory, and Malama Maunalua will use satellite-tracked ... south shore in an effort to better understand why ...
... finds that propofol, a well-known anesthesia medication, has a low ... The study, led by a pediatric anesthesiologist now at ... adverse events and no long term complications when propofol was ... to be still for long periods of time. ...
Cached Biology News:Tracking coral larvae to understand Hawai'i reef health 2Propofol poses low risk in pediatric imaging studies, but risk increases with anesthesia duration 2
(Date:5/28/2015)... N.J. , May 28, 2015 Celsion ... that it has received commitments from two institutional healthcare ... of the Company,s common stock in an at-the-market registered ... to purchase common stock. The Company entered ... to which the Company agreed to sell an aggregate ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, non-profit ... sciences industry in northern region of Texas, held ... Foundry in Dallas on April 27, 2015. The ... broad spectrum of biotech professionals from the North ... in partnering with key life sciences organizations both ...
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Inc. (Nasdaq: SGMO ) today announced that the ... Wednesday, April 30,2008, after the market closes. The press ... p.m. PT, which will be open to the public ... will review,the financial results and discuss other business matters., ...
... Schering-Plough,Corporation (NYSE: SGP ) today announced two ... franchises in Europe. These agreements are,in connection with ... part,of its October 2007 clearance of Schering-Plough,s acquisition ... N.V., In two separate agreements, Pfizer and ...
... the First Eight Months Since its Introduction in the ... VYVANSE has Achieved Over One Million Prescriptions,In ... Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity ... /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global ...
Cached Biology Technology:Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 2FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 3FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 4FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 5FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 6FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 7FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults 8
... designed for RNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Aptamer Microarray contains greater than 1500 known ...
... mouse embryonic stem cells to dopaminergic neurons. ... where they are mainly located in the ... the retrorubral field. These dopaminergic (DA) neurons ... ( e.g.projections to the caudate nucleus, putamen ...
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive DNA/RNA ...
... Microarrays designed for DNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
Biology Products: